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Pancreaticopleural ﬁstula is a rare complication of acute and chronic pancreatitis. This usually presents with chest symptoms due
to pleural eﬀusion, pleural pseudocyst, or mediastinal pseudocyst. Diagnosis requires a high index of clinical suspicion in patients
who develop alcohol-induced pancreatitis and present with pleural eﬀusion which is recurrent or persistent. Analysis of pleural
ﬂuid for raised amylase will conﬁrm the diagnosis and investigations like CT. Endoscopic retrograde cholangiopancreaticography
(ECRP) or magnetic resonance cholangiopancreaticography (MRCP) may establish the ﬁstulous communication between the
pancreas and pleural cavity. The optimal treatment strategy has traditionally been medical management with exocrine suppression
with octreotide and ERCP stenting of the ﬁstulous pancreatic duct. Operative therapy considered in the event patient fails to
respond to conservative management. There is, however, a lack of clarity regarding the management, and the literature is reviewed
here to assess the present view on its pathogenesis, investigations, and management.
1.Introduction
Pancreaticopleural ﬁstula has been recognized as a clinical
entity since case reports were published in late 1960s [1].
Since that time, pancreaticopleural ﬁstulae and pancreatic
ascites have been termed as internal pancreatic ﬁstulae which
share common pathogenesis which includes the disruption
of main pancreatic duct, resulting in leakage of pancreatic
ﬂuid [2–6]. This rare entity may be seen in patients with
acute and chronic pancreatitis or may follow traumatic
and surgical disruption of the pancreatic duct [2–6]. It is
characterized by massive pleural ﬂuid and has a tendency to
recur following treatment. While conservative management
with pancreatic duct stenting and inhibition of pancreatic
secretion with octreotide may achieve closure of ﬁstula in 31
to45%ofcases,surgeryleadstohealingin80to90%ofcases
but carries a mortality up to 10% [2–6].
2. Incidence
Pleuraleﬀusionduetopancreaticopleuralﬁstulaisextremely
unusual accounting for less than 1% of cases [7]. It is
seen in 3 to 7% of patients with pancreatitis [8], and
a combined frequency of internal pancreatic ﬁstula (pancre-
aticascitesandpancreaticopleuralﬁstulae)isseeninbetween
0.4 and 7% of chronic pancreatitis patients and in 6 and
14% of patients with pseudocyst [5, 6]. Pancreaticopleural
ﬁstulae are however more unusual than pancreatic ascites. It
usually presents as large recurrent pleural eﬀu s i o ni ne i t h e r
pleural space, but left-sided eﬀu s i o ni sm o r ec o m m o na n d
are reported to account for 76% of cases [2–6].
3.Pathophysiology
The development of pancreaticopleural ﬁstula is usually a
consequence of leak from an incompletely formed or rup-
tured pseudocyst [2–6] or in a minority of cases due to direct
pancreatic duct leak [4–6]. The ﬁstulous tract passes either
through the aortic or oesophageal diaphragmatic oriﬁce
or directly transdiaphragmatically. Similar pathophysiology
and aetiology apply to pancreatic ascites and pancreatic
pleural eﬀusion. If the pancreatic duct disruption occurs
anteriorly and is not walled oﬀ, a pancreaticoperitoneal
ﬁstula will develop that will manifest as ascites [2–6]. If
the disruption develops posteriorly, pancreatic secretion will
ﬂow into retroperitoneum and may dissect through aortic2 Diagnostic and Therapeutic Endoscopy
or oesophageal hiatus into mediastinum and form a pleural
ﬁstula or present as mediastinal pseudocyst which in turn
ruptures into the pleural cavity and forms a pleural ﬁstula
[4–6].
4.ClinicalFeatures
Middle-aged men between 40 and 50 years who have history
of chronic alcoholism and develop pancreatitis, form the
common group of patients who develop pancreaticopleural
ﬁstula [3–6]. About half of the patients do not have history
of pancreatitis [6]. Trauma is less common cause and is seen
in 0.5% of the cases [6]. Pancreatic pseudocyst may be noted
in 69 to 77% of the patient, who develop pancreaticopleural
ﬁstula[4–6].Theclinicalmanifestationsareoftenmisleading
as symptoms are usually associated with signiﬁcant pleural
eﬀusion and consist of dyspnea, cough, chest pain fever and
septicaemia [2–8]. Pulmonary symptoms are more common
than abdominal symptoms and are usually the presenting
symptom with dyspnea being the most common [7, 8].
Rarely do patients complain of abdominal pain typical of
acute pancreatitis. The average duration of symptoms is 5.6
weeks [2, 4, 6].
Pleural eﬀusion are predominately left sided; however,
right-sided and bilateral eﬀusion occurs in 19% and 14%
of patient’s, respectively [3]. Pleural eﬀusion of this nature
tends to be large and recurrent despite repeated thoracocen-
tesis [2–6]. Many patients go through extensive pulmonary
evaluation before pancreas is identiﬁed as the site of primary
pathology. The pleural eﬀusion is associated with ascites in
20% and pericarditis in 4% [9]. The major complication
in these patients is superinfection which contributes to
signiﬁcant morbidity and mortality. In a review of 113
cases from Japan, 98% of the cause of pancreaticopleural
ﬁstula was related to chronic relapsing pancreatitis due to
chronic alcoholism [10]. Chest pain was the predominant
symptom and was noted in 68% with other symptoms being
abdominal symptoms and pancreatic ascites in 24% and
12%, respectively [10].
5.Diagnosis
Frequently the diagnosis is delayed [2–6, 10]. The time to
diagnosis is reported to range from 12 to 49 days [4]. Delay
in diagnosis is a critical issue. It needs a high index of
clinical suspicion in those with a history of acute pancreatitis
and alcohol abuse presenting with a pleural eﬀusion which
reformsrelativelyrapidlyafteraspirationandforwhichthere
is no obvious other cause.
Pleural eﬀusion associated with pancreaticopleural ﬁs-
tula should be distinguished from the small reactive, self-
limiting left-sided eﬀusion that commonly occurs in 3
to 17% of patients with acute pancreatitis [3]. A pan-
creaticopleural ﬁstula may be suspected on the basis of
the clinical picture and analysis of pleural ﬂuid following
thoracocentesis which reveals an extremely elevated pleural
ﬂuid amylase level (normal <150IU/L), lipase, and high
albumin content (>3g/dL)[2–6]. The serum amylase on the
other hand is usually mildly elevated but not invariably and
is thought to be partly secondary to reabsorption of amylase
from pleural surfaces [4–6]. The diﬀerential diagnosis for
amylase-rich pleural eﬀusion includes acute pancreatitis,
cancer of lung, rectum, breast, female reproductive system,
metastatic carcinoma, pneumonia, oesophageal perforation,
lymphoma, leukaemia, liver cirrhosis, hydronephrosis, and
pulmonary tuberculosis [11].
A simple chest radiography is the ﬁrst line of investiga-
tion, but this provides only limited information of the ﬂuid
collection in pleural cavity [3, 4]. A CT scan of the chest
and abdomen is valuable in the diagnosis [2–6]. Currently
CT is the gold standard for investigating pleural eﬀusion
[3, 4]. It is very useful in determining the site and size of
eﬀusion,butoverallabilitytoprovideaccuratedelineationof
the ﬁstula is disputable [3, 11]. CT abdomen in addition will
reveal changes of pancreatitis and identify other associated
abnormalities such as pancreatic pseudocysts [2–6]. CT scan
may demonstrate the ﬁstulous tract especially if obtained
immediately after an ERCP. Magnetic resonance cholan-
giopancreaticography is reported to be particularly useful in
demonstratingthepancreaticpathologyandtheﬁstula[5,8].
It is a noninvasive alternative to ERCP, visualizes the duct
beyond the strictures, depicts parenchymal atrophy, ductal
anatomy and small intrapancreatic and extrapancreatic
pseudocyst, peripancreatic collection, or pancreaticopleural
ﬁstula, and is useful where ERCP fails to give adequate
information [5, 8].
The diagnosis may be conﬁrmed with ERCP although
it may not always be possible to demonstrate the ﬁstulous
tract[6].ERCPmaynotdemonstratetheﬁstulainpatientsin
whom the site of ductal disruption exists in more distal side
than the site where a ductal obstruction exists. In these cases,
CTorMRCPmaybehelpful.ERCPleadstodiagnosisin80%
of cases and demonstrates the ﬁstulous tract in 59% to 74%
of the cases [3, 4, 11]. Visualisation of the entire pancreatic
ductal tree is useful in planning a rational surgical approach,
particularly in deciding between a resection and a drainage
procedure [2, 6].
6. Treatment
Due to high failure rate in the past of simple conservative
management including drainage of chest and keeping the
patient nil per oral, the patient would invariably require
surgical intervention. Following the encouraging results with
octreotide administration and stent placement, success rate
of conservative management has signiﬁcantly improved [2–
7,10,11].Theavailabletreatmentmodalitiesnowinclude(1)
conservative/medical management (octreotide and thora-
centesis), (2) ERCP plus/minus endoscopic pancreatic stent
placement, and (3) surgery [2–7, 10, 11].
The aim of the medical treatment is to reduce stim-
ulation to pancreatic exocrine secretions [2, 4, 6, 10, 11].
Medical treatment constitutes thoracocentesis and/or tube
thoracostomy, both of which encourage apposition of serosal
surfaces and symptom relief along with the administration
of somatostatin analogues [4, 11]. The duration of thisDiagnostic and Therapeutic Endoscopy 3
treatment by itself varies, but in the past when endoscopic
stenting was not available, conservative management did not
exceed2to4weeks[6,9].Withinthistimeiftherewasfailure
to respond to conservative management, which includes
failure of pleural eﬀusion and or superinfection to clear,
then surgical intervention would be the optimal treatment.
Presently,duetothesuccessachievedwithoctreotideadmin-
istration and placement of stent in the duct, longer period
of conservative management is employed; this includes
octreotide being continued from 2.5 to 6 months and chest
being drained from 6 to 24 days [4]. Octreotide is given as
an initial dose of 50ug, administered subcutaneously three
times a day, and the dose is titrated based upon the ﬁstula
output, the maximal dose employed being 250ug three times
daily [4, 11]. It is reported that octreotide signiﬁcantly
reduces ﬁstula output and decreases the time to ﬁstula
closure [11]. Measures like the prohibition of oral intake,
nasogastrictubeinsertionandtotalparenteralnutritionused
in the past are no longer necessary [4–6, 11]. Complications
related to nonoperative therapy including malnutrition,
central venous catheter infections, deep vein thrombosis,
and sepsis associated with intestinal mucosal atrophy from
prolonged fasting have been signiﬁcantly reduced following
the use of octreotide and pancreatic stent placement [6, 12].
Moreover,substantialoverallmorbidityandcostaccrueddue
to prolonged hospitalization are reduced [4, 6, 12].
ERCP and stent placement have revolutionized the con-
cept of nonsurgical management in these patients [2–7]. The
potential beneﬁts of ERCP include papillary sphincterotomy
in cases of sphincter of Oddi dysfunction, dilatation of
stenosis of the main pancreatic duct, and extraction of
stones from the main pancreatic duct with or without
extracorporeal lithotripsy, all of which could contribute to
persistence of the ﬁstula [9, 11, 13, 14]. Mere endoscopic
papillotomy may precede the insertion of the stent as a
lesser option in those cases where stenting fails [4]. When
stents are placed into the main pancreatic duct, patient’s
pain caused by ductal pressure may be relieved; moreover,
pseudocysts that communicate with the main pancreatic
duct may be drained [4–7, 13–15]. ERCP also facilitates
drainage of ﬁstula by the insertion of nasopancreatic drains
for 1 week, followed by placement of an endoprosthesis in
the pancreatic duct [6, 13–15]. The distinct advantage of
naso pancreatic drain in contrast to stent placement is that
itallowspancreaticogramstobeobtainedrepeatedlywithout
further invasive procedures. It also allows application of low
intermittent suction, which may potentially facilitate closure
o fal e a ko rﬁ s t u l a[ 15]. However, the major drawbacks
include the necessity for continued hospitalisation and
patient discomfort due to the presence of the tube in the
nose [15]. ERCP in general is an invasive procedure, and the
availability of expertise in endoscopic placement of stent is a
bare necessity [6, 11].
Themainobjectiveofstentplacementotherthandecom-
pressing the duct is to bridge the site of duct disruption if
possible [6, 13–15]. Most ﬁstulae appear to arise from head
or body of the pancreas and are thus amenable to bridging
with a pancreatic stent [6, 13, 15]. However bridging may
not be feasible in patients in whom the ﬁstula arises from
the tail of the pancreas and the stent may have to be placed
close to the duct disruption [6, 13–15]. Bridging pancreatic
stents helps to close the ﬁstula rapidly by decreasing the
ductalpressureandabolitionofpancreaticpressuregradient,
achieved by bypassing the sphincter of Oddi and stricture
and by mechanically blocking the ﬁstula lumen. The stents
used for this purpose are either 5Fr or 7Fr size [6, 13–
15]. Fistulae from a pseudocyst which is no longer in direct
communication with pancreatic ductal system may heal
spontaneously [6, 15].
Theprincipalaimofthetreatmentwithstentistoachieve
drainage of ducts with ﬁstulae in short term and drainage
of the stenosed pancreatic duct in long term (2–12 months)
[15]. The optimum duration of drainage for ﬁstulae is
unknown at present. This can vary from 4 to 12 weeks [6, 9].
One approach would be to assess the persistence of ﬁstula by
repeating ERCP at 6 weekly intervals and documenting the
passage of dye into the chest [4]. The concern, however, of
long-term use of stent is that it itself causes ductal changes
that do not always regress after its removal [16]. As the
data on the long-term consequence of pancreatic duct stent
placement is lacking, a deﬁnite opinion is diﬃcult to draw
[6, 12]. Signiﬁcant proportion of these patients, however,
may still require surgery particularly for persistent, recurrent
ﬂuid collections secondary to stenosis or disruption of the
main pancreatic duct [17]. The issue of how long to continue
with endoscopic treatment is largely unresolved [4].
Surgical treatment is safe and eﬀective and is appropriate
either when medical management fails or where underlying
condition requires surgical intervention [2–7, 10, 11]. The
main indications for surgery are failure of conservative and
endoscopic treatment, obstruction of pancreatic duct that
cannot be managed endoscopically and a symptomatic ﬁt
patient[2–7,10,11].Surgicaltreatmentincludeseithersome
form of a pancreatic resection (Figure 1)o re n t e r o p a n c r e a t i c
anastomosis to the site of pancreatic duct leakage or to the
pseudocyst [4, 7, 11]. If there is an obstruction of the main
pancreatic duct proximal to the ﬁstula, surgical treatment is
necessary to decompress the obstructed duct with or without
excision of the involved portion of the obstructed pancreas
[2–6, 10, 11]. Cystogastrostomy, cystojejunostomy and distal
and middle pancreatectomy are appropriate options in the
setting of symptomatic pancreatic pseudocysts or pancreatic
duct obstruction [2–6, 11]( Figure 1).
In summary the ﬁrst line of treatment should be chest
drain, octreotide therapy, and ERCP with an attempt at
pancreatic stent insertion. Endoscopic pancreatic stenting
is eﬀective therapeutic option associated with minimal
morbidity and mortality, and combined with somatostatin
analogues it can shorten the duration of hospital stay.
Surgical intervention is the 2nd line of treatment with an
appreciable morbidity and mortality.
King et al. based on the review of 63 adult patients in
the literature between 1970 and 2008 made the following
observation [2]. The majority of the patients were male
(71%), and there was predominance of alcohol-induced
chronic pancreatitis (51%). Complications were noted in
16% of patients and death in 3%. Most patients were treated
initially with medical therapy (87%). Medical therapy was4 Diagnostic and Therapeutic Endoscopy
 
 
Figure 1:Distalpancreatectomyspecimenofapatientwithpancre-
aticopleural ﬁstula in chronic pancreatitis who failed to respond to
conservative management. Pancreatic duct with strictured segment
(curved arrow) and site of leak (straight arrow) seen.
deemed to have failed after an average period of 35 ±5d a y s .
Total duration of therapy for patients in whom operative
intervention was required after attempted medical manage-
ment was 40 ± 6 days which was greater than the surgery
alone cohort [2]. Based on this review, they concluded
that the traditional strategy of initial medical management
followed by operative treatment is questionable. Medical
therapy was found to be successful only in 31% of the time
whereas operation therapy was more than 3 times likely to
succeed (94%) when applied as either an initial strategy or
after failed medical management [2].
Analyzing the advantages of early surgical intervention
based on the review, they felt that failed initial attempts at
medical therapy would lead to longer periods of treatment
than in those who underwent operative treatment early on.
Moreover, the time spent on treating patients medically was
50% more than that was devoted to postoperative recovery,
indicating that earlier operative intervention may have
decreased the duration of therapy required for resolution of
ﬁstulaby50%[2].Furtheradvantagenotedwasshorterpost-
operative recovery time for patients experiencing morbidity
(16±3v e r s u s2 4±8 days) which may reﬂect the widespread
trend toward shorter postoperative hospital stay in recent
years [2]. It was also noted that 70% of the complications
that followed surgical intervention was seen in patients in
whom conversion from medical to operative therapy was
necessary. These complications included leaks, recurrence of
ﬁstula, intra-abdominal infection, wound infection, and the
development of diabetes. In general, conservative treatment
for pancreaticopleural ﬁstula has a success rate of 30–60%,
with a recurrence rate of 15% and mortality of 12%; in
contrast, operative therapy has a success rate of 90% with up
to 18% recurrence rate [2].
7. Conclusion
Pancreaticopleural ﬁstula is diﬃcult to diagnose and at
times diﬃcult to treat. They require a high index of clinical
suspicion to diagnose, particularly in the setting of recurrent
pleural eﬀusions with coexisting history of pancreatitis or
alcohol abuse. The predominant symptoms are related to
chest rather than abdomen. Early pleural ﬂuid amylase
testing will avoid delayed diagnosis. The initial line of
treatment includes drainage of the eﬀusion, the inhibition of
pancreaticsecretionswithoctreotideandpossiblyERCPplus
stenting of the pancreatic duct. While surgery is generally
considered to be appropriate when medical measures fail or
if there is an associated or complicated pseudocyst, there are
others who support an early surgical intervention to reduce
the recovery time and increase the success rate.
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